Vitiligo in 2 patients receiving vemurafenib for metastatic melanoma

Journal of the American Academy of Dermatology

Volumn 69, Issue 1, 2013, Pages

  Alonso Castro, Leticia ^a   Ríos Buceta, Luis ^a   Vano Galvan, Sergio ^a   Moreno, Carmen ^a   Soria Rivas, Ainara ^a   Jaén, Pedro ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; B RAF KINASE; DACARBAZINE; IPILIMUMAB; VEMURAFENIB;

ADULT; AXILLARY LYMPH NODE; BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CASE REPORT; CELL LOSS; COMPUTER ASSISTED TOMOGRAPHY; CUTANEOUS MELANOMA; DEPIGMENTATION; DRUG MEGADOSE; DRUG RESPONSE; FACE; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; INGUINAL LYMPH NODE; LETTER; LUNG METASTASIS; LYMPH NODE METASTASIS; MELANOCYTE; METASTATIC MELANOMA; NECK; PRIORITY JOURNAL; SKIN BIOPSY; SKIN DEFECT; TREATMENT DURATION; TREATMENT RESPONSE; VITILIGO; WOOD LAMP;

EID: 84879072709     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2013.01.012     Document Type: Article

References (5)

1. J.A. Sosman, K.B. Kim, and L. Schuchter Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib N Engl J Med 366 2012 707 714
2. R. Sinha, K. Edmonds, J.A. Newton-Bishop, M.E. Gore, J. Larkin, and L. Fearfield Cutaneous adverse events associated with vemurafenib in patients with metastatic melanoma: practical advice on diagnosis, prevention and management of the main treatment-related skin toxicities Br J Dermatol 167 2012 987 994
3. V. Huang, D. Hepper, M. Anadkat, and L. Cornelius Cutaneous toxic effects associated with vemurafenib and inhibition of the BRAF pathway Arch Dermatol 148 2012 628 633
4. M. Maio Melanoma as a model tumour for immuno-oncology Ann Oncol 23 Suppl 8 2012 viii10 viii14
5. K.T. Byrne, and M.J. Turk New perspectives on the role of vitiligo in immune responses to melanoma Oncotarget 2 2011 684 694